Although preclinical, epidemiological and prior clinical trial data suggest that green tea catechins (GTCs) may reduce prostate cancer (PCa) risk, several preclinical studies and case reports have reported liver toxicities and acute gastrointestinal bleeding. Based on these observations, regulatory bodies have required stringent inclusion criteria with frequent, excessive toxicity monitoring and early stopping rules in clinical trials. These requirements have impeded recruitment and retention of subjects in chemoprevention trials and subsequent progress in agent development efforts.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
We conducted a placebo-controlled, randomized clinical trial of Polyphenon E® (PolyE®), a proprietary mixture of decaffeinated GTCs, containing 400 mg (-)-epigallocatechin-3-gallate (EGCG) per day, in 97 men with high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP). PolyE® containing 200 mg EGCG was administered with food, BID. A secondary study endpoint in this trial was a comparison of the overall one-year treatment related adverse events and grade 3 or higher adverse event on the two study arms. Monthly assessments of toxicity (CTCAE 4.0), concomitant medications and organ function, including hepatic panel, PT/PTT and LDH, were performed.
Daily intake of a standardized, decaffeinated, catechin mixture containing 200 mg EGCG BID taken with food for 1 year accumulated in plasma and was well tolerated and did not produce treatment related adverse effects in men with baseline HGPIN or ASAP.
The current data provides evidence of safety of decaffeinated, catechin mixture containing 200 mg EGCG BID to be further tested for prostate cancer prevention or other indications.
Oncotarget. 2016 Oct 25 [Epub]
Nagi B Kumar, Julio Pow-Sang, Philippe E Spiess, Jong Park, Raoul Salup, Christopher R Williams, Howard Parnes, Michael J Schell
H. Lee Moffitt Cancer Center & Research Institute, Inc., Cancer Epidemiology, 12902 Magnolia Drive, MRC/CANCONT, Tampa, FL 33612-9497, USA., H. Lee Moffitt Cancer Center & Research Institute, Inc., Genitourinary Oncology, 12902 Magnolia Drive, WCB-GU PROG, Tampa, FL 33612-9497, USA., University of South Florida College of Medicine, Urology, 12901 Bruce B. Downs Blvd.Tampa, FL 33612, USA., University of Florida - Jacksonville, UF Health Jacksonville, Urologic Oncology, Jacksonville, FL 32209, USA., National Cancer Institute, Division of Cancer Prevention, 10 CENTER DR Bldg. 10, Bethesda, MD 20892, USA., Moffitt Cancer Center & Research Institute, Inc., Biostatistics and Bioinformatics, 12902 Magnolia Drive, MRC/BIOS, Tampa, FL 33612-9497, USA.